Investigation: FTC Demand Teva Inhaler Patents Down – What’s at Stake?
Washington, D.C. – The Federal Trade Commission (FTC) has initiated an inquiry into Teva Pharmaceuticals’ practices, specifically their refusal to remove around two dozen patents associated with their asthma and COPD inhalers. This investigation follows the FTC’s demand for Teva to furnish internal communications, analysis, and financial data related to the disputed patents listed in the Orange Book, a federal registry. The FTC alleges that pharmaceutical companies like Teva have been making minor alterations to …